Avelumab in First-line NSCLC (JAVELIN Lung 100)
Public ClinicalTrials.gov record NCT02576574. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III, Open-label, Multicenter Trial of Avelumab (MSB0010718C) Versus Platinum-based Doublet as a First-line Treatment of Recurrent or Stage IV PD-L1+NSCLC
Study identification
- NCT ID
- NCT02576574
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.
- Industry
- Enrollment
- 1,214 participants
Conditions and interventions
Conditions
Interventions
- Avelumab Drug
- Avelumab Weekly Drug
- Carboplatin Drug
- Cisplatin Drug
- Gemcitabine Drug
- Paclitaxel Drug
- Pemetrexed Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 28, 2015
- Primary completion
- Dec 5, 2021
- Completion
- Jan 28, 2024
- Last update posted
- Jan 30, 2025
2015 – 2024
United States locations
- U.S. sites
- 21
- U.S. states
- 19
- U.S. cities
- 21
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Clearview Cancer Institute | Huntsville | Alabama | 35805 | — |
| Arizona Center for Cancer Care | Surprise | Arizona | 85374 | — |
| Sharp Memorial Hospital | San Diego | California | 92123 | — |
| University Cancer Institute | Boynton Beach | Florida | 33426 | — |
| South Georgia Medical Center | Valdosta | Georgia | 31602 | — |
| Christus Cancer Treatment Center | Shreveport | Louisiana | 71105 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| St. Vincent Frontier Cancer Center | Billings | Montana | 59102 | — |
| Nevada Cancer Research Foundation | Las Vegas | Nevada | 89106 | — |
| San Juan Oncology Associates | Farmington | New Mexico | 87401 | — |
| Novant Health Oncology Specialists | Kernersville | North Carolina | 27284 | — |
| Mercy Research | Oklahoma City | Oklahoma | 73120 | — |
| Kaiser Permanente Northwest | Portland | Oregon | 97227 | — |
| Lancaster Cancer Center | Lancaster | Pennsylvania | 17605 | — |
| Cookeville Regional Medical Center | Cookeville | Tennessee | 38501 | — |
| Thompson Cancer Survival Center | Knoxville | Tennessee | 37916 | — |
| Coastal Bend Cancer Center | Corpus Christi | Texas | 78404 | — |
| Oncology Consultants, P.A. | Houston | Texas | 77030 | — |
| University of Vermont Medical Center | Burlington | Vermont | 05401-1473 | — |
| Northwest Medical Specialties, PLLC | Tacoma | Washington | 98405 | — |
| Cheyenne Regional Medical Center | Cheyenne | Wyoming | 82001 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 328 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02576574, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 30, 2025 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02576574 live on ClinicalTrials.gov.